Allied Corp Completes First German Medical Cannabis Delivery as European Demand Accelerates

Allied Corp is pleased to announce that it has officially landed its first medical cannabis shipment in Germany, marking a key operational milestone in the company’s European expansion strategy.

This delivery follows Allied’s recent CUMCS-GACP certification (read here) and reinforces its ability to operate within one of the most demanding pharmaceutical cannabis markets globally - meeting stringent quality standards, while navigating complex supply chains from its cultivation facility in Colombia to Germany.

Delivering on Demand: First German Shipment Lands, More on the Way

This first shipment was delivered to a licensed pharmaceutical distributor in Germany, with the majority of the product already pre-sold into pharmacies - underscoring alignment between Allied’s production and real market demand.

Further to initial traction, the client has confirmed two additional batches, currently being manufactured at Blossom, Allied’s EU-GMP partner facility in Portugal, and expected to land in Germany within the next 2 to 3 months. Allied is also preparing additional shipments to meet contracted demand across Germany, the UK, Switzerland, Italy, and Malta, among others.

Proving Our Supply Chain and Quality Standards

Delivering compliant product to Germany not only reaffirms Allied’s ability to meet Europe’s most stringent pharmaceutical thresholds, but also proves the strength of our supply chain into tightly regulated jurisdictions.

In fact, the product was cultivated at Allied’s GACP-certified facility in Colombia, then shipped earlier this year to Blossom in Portugal for API and primary processing. It successfully passed European Pharmacopeia quality testing (Table C), including strict thresholds for microbial content, pesticide residues, and heavy metals, among others, an achievement few cultivators from Colombia have consistently achieved.

Germany sets the bar - and Allied has proven it can meet it.

A Growing European Market

This milestone comes amid a period of accelerating demand in Europe’s medical cannabis markets. In Germany alone, the medical cannabis market is projected to surpass €1 billion by 2028, up from an estimated €420 million in 2024 [1] - driven by expanded patient access, lower prescription barriers, and the rescheduling of cannabis as a non-narcotic in 2024.

Momentum continues across the continent. Just this week, Slovenia’s National Assembly passed a bill to legalize medical cannabis, joining a wave of countries expanding access and formalizing regulation across Europe (read here).

With a compliant supply chain in motion, established partners across multiple jurisdictions, and GACP certification secured, Allied is well-positioned to continue to supply Europe’s most advanced and demanding pharmaceutical cannabis markets.

If you’re active in the space or want to exchange on the industry, we welcome the opportunity to connect.

Investor Relations : ir@allied.health

Website : https://www.allied.health

Disclaimer and Forward-Looking Statements:

No regulatory authority assumes responsibility for the accuracy or adequacy of this release.

This press release includes certain statements that may be deemed "forward-looking statements" under U.S. and Canadian securities laws. Forward-looking statements relate to Allied Corp.’s anticipated developments, strategic objectives, performance, and market opportunities. These include, but are not limited to, statements regarding Allied’s growth in Colombia, Kelowna, Nevada, and other key locations; intellectual property filings; joint development and manufacturing initiatives; and planned product introductions.

Forward-looking statements can often be identified by terms such as "anticipates," "believes," "expects," "intends," "plans," "will," "may," and similar expressions. These statements are based on current assumptions, projections, and management’s experience, but are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Notable risks include, but are not limited to, regulatory risks associated with the cannabis industry and market changes ; risks related to competition within the cannabis and medical industries; risks related to potential operational and logistical challenges; risks related to market demand; risks related to economic conditions impacting growth and profitability; risks related to potential delays or adverse changes in project locations or expansion plans; as well as other risks.

Though Allied endeavors to identify important factors that may impact actual outcomes, other unknown factors may also cause results to vary. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

[1] Prohibition Partners. (October 2024) .